198 related articles for article (PubMed ID: 28560068)
1. HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer.
Shan W; Jiang Y; Yu H; Huang Q; Liu L; Guo X; Li L; Mi Q; Zhang K; Yang Z
Am J Cancer Res; 2017; 7(5):1213-1226. PubMed ID: 28560068
[TBL] [Abstract][Full Text] [Related]
2. An integrated genomic analysis of Tudor domain-containing proteins identifies PHD finger protein 20-like 1 (PHF20L1) as a candidate oncogene in breast cancer.
Jiang Y; Liu L; Shan W; Yang ZQ
Mol Oncol; 2016 Feb; 10(2):292-302. PubMed ID: 26588862
[TBL] [Abstract][Full Text] [Related]
3. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
4. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
5. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.
Weichert W; Röske A; Gekeler V; Beckers T; Ebert MP; Pross M; Dietel M; Denkert C; Röcken C
Lancet Oncol; 2008 Feb; 9(2):139-48. PubMed ID: 18207460
[TBL] [Abstract][Full Text] [Related]
6. Genotranscriptomic meta-analysis of the CHD family chromatin remodelers in human cancers - initial evidence of an oncogenic role for CHD7.
Chu X; Guo X; Jiang Y; Yu H; Liu L; Shan W; Yang ZQ
Mol Oncol; 2017 Oct; 11(10):1348-1360. PubMed ID: 28649742
[TBL] [Abstract][Full Text] [Related]
7. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.
Zhao H; Yu Z; Zhao L; He M; Ren J; Wu H; Chen Q; Yao W; Wei M
Jpn J Clin Oncol; 2016 Oct; 46(10):893-902. PubMed ID: 27432453
[TBL] [Abstract][Full Text] [Related]
8. Histone modifiers and marks define heterogeneous groups of colorectal carcinomas and affect responses to HDAC inhibitors in vitro.
Lutz L; Fitzner IC; Ahrens T; Geißler AL; Makowiec F; Hopt UT; Bogatyreva L; Hauschke D; Werner M; Lassmann S
Am J Cancer Res; 2016; 6(3):664-76. PubMed ID: 27152243
[TBL] [Abstract][Full Text] [Related]
9. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Jang YG; Hwang KA; Choi KC
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
[TBL] [Abstract][Full Text] [Related]
10. Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast.
Seo J; Min SK; Park HR; Kim DH; Kwon MJ; Kim LS; Ju YS
J Breast Cancer; 2014 Dec; 17(4):323-31. PubMed ID: 25548579
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
12. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
[TBL] [Abstract][Full Text] [Related]
13. An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.
Hanigan CL; Van Engeland M; De Bruine AP; Wouters KA; Weijenberg MP; Eshleman JR; Herman JG
Gastroenterology; 2008 Nov; 135(5):1654-1664.e2. PubMed ID: 18834886
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity.
Harms KL; Chen X
Cancer Res; 2007 Apr; 67(7):3145-52. PubMed ID: 17409421
[TBL] [Abstract][Full Text] [Related]
15. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
[TBL] [Abstract][Full Text] [Related]
16. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
17. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer.
Damaskos C; Psilopatis I; Garmpi A; Dimitroulis D; Nikolettos K; Vrettou K; Sarantis P; Koustas E; Kouraklis G; Antoniou EA; Karamouzis MV; Nikolettos N; Tsikouras P; Marinos G; Kontomanolis E; Kontzoglou K; Garmpis N
Cancers (Basel); 2024 Jan; 16(1):. PubMed ID: 38201636
[TBL] [Abstract][Full Text] [Related]
20. Curcumin: A Natural Pan-HDAC Inhibitor in Cancer.
Soflaei SS; Momtazi-Borojeni AA; Majeed M; Derosa G; Maffioli P; Sahebkar A
Curr Pharm Des; 2018; 24(2):123-129. PubMed ID: 29141538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
